Anzeige
Mehr »
Mittwoch, 26.11.2025 - Börsentäglich über 12.000 News
Kupfer-Superzyklus voraus: Dieses Top-Projekt in Nevada wird jetzt zum echten Investmentcase
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1XFUX | ISIN: IL0011313900 | Ticker-Symbol: GPH
Lang & Schwarz
26.11.25 | 07:00
6,500 Euro
-100,00 % -6,500
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
GALMED PHARMACEUTICALS LTD Chart 1 Jahr
5-Tage-Chart
GALMED PHARMACEUTICALS LTD 5-Tage-Chart
RealtimeGeldBriefZeit
6,4006,60007:00

Aktuelle News zur GALMED Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
14:42Galmed GAAP EPS of -$0.33 beats by $0.211
14:30Galmed Pharmaceuticals Ltd.: Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update120TEL AVIV, Israel, Nov. 26, 2025 /PRNewswire/ -Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company...
► Artikel lesen
13:57Galmed Pharmaceuticals Ltd. - 6-K, Report of foreign issuer-
GALMED Aktie jetzt für 0€ handeln
18.11.Galmed Pharmaceuticals Ltd.: Galmed Announces Meaningful Top Line Results from AM-001 Study of Aramchol Meglumine120The top-line results showed that bioavailability of Aramchol meglumine 400mg and 200mg granules is considerably greater, higher by 5-fold and 3-fold respectively...
► Artikel lesen
17.11.Galmed meldet erhöhte Wirksamkeit bei Krebstherapie durch Dreifach-Kombination5
17.11.Galmed reports 3-drug combo enhances cancer treatment efficacy2
17.11.Galmed Pharmaceuticals Ltd.: Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo and In-vitro575The top-line results from the study showed that the 3-drugs' synergistic effect has the potential as a new fixed-dose combination treatment, enhancing the effect...
► Artikel lesen
17.11.Galmed Pharmaceuticals Ltd. - 6-K, Report of foreign issuer3
28.10.Galmed Pharmaceuticals Ltd. - 6-K, Report of foreign issuer7
19.09.Galmed Pharmaceuticals beruft Jährliche Hauptversammlung für den 28. Oktober ein7
19.09.Galmed Pharmaceuticals Ltd. - S-8, Securities to be offered to employees in employee benefit plans2
19.09.Galmed Pharmaceuticals Ltd. - 6-K, Report of foreign issuer3
28.08.Galmed Pharmaceuticals Ltd.: Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update189TEL AVIV, Israel, Aug. 28, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company...
► Artikel lesen
25.08.Galmed to invest up to $10M in digital assets as part of new strategy14
25.08.Galmed Pharmaceuticals Ltd. - 6-K, Report of foreign issuer1
18.08.Galmed files to sell 7.5M shares of common stock for holders3
18.08.Galmed Pharmaceuticals Ltd. - F-1, Registration statement for certain foreign private issuers3
15.08.Galmed Pharmaceuticals Ltd. - 6-K, Report of foreign issuer1
24.07.Galmed Pharmaceuticals Ltd. - 6-K, Report of foreign issuer3
22.05.Galmed Pharmaceuticals Ltd.: Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update593TEL AVIV, Israel, May 22, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company...
► Artikel lesen
Weiter >>
24 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1